Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS.
Pancreas. 2019 Oct;48(9):1119-1125. doi: 10.1097/MPA.0000000000001402.
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK.
Nat Commun. 2022 Oct 27;13(1):6418. doi: 10.1038/s41467-022-34242-4.
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male.
Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T.
Hematol Oncol Stem Cell Ther. 2014 Sep;7(3):109-15. doi: 10.1016/j.hemonc.2014.03.002. Epub 2014 Apr 29.
Vasoactive intestinal peptide.
Said SI.
J Endocrinol Invest. 1986 Apr;9(2):191-200. doi: 10.1007/BF03348097.
Verner-Morrison syndrome. Literature review.
Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Mărginean O, Iacob ER, Iacob D, Motoc AGM, Boia ES.
Rom J Morphol Embryol. 2017;58(2):371-376.
A case of VIPoma.
Crawford L, Amin V.
Int J Obstet Anesth. 2022 Nov;52:103600. doi: 10.1016/j.ijoa.2022.103600. Epub 2022 Sep 28.
VIPoma syndrome.
Krejs GJ.
Am J Med. 1987 May 29;82(5B):37-48. doi: 10.1016/0002-9343(87)90425-6.
Pancreas Imaging.
Stevens KJ, Lisanti C.
2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Pancreatic neuroendocrine tumors.
Batcher E, Madaj P, Gianoukakis AG.
Endocr Res. 2011;36(1):35-43. doi: 10.3109/07435800.2010.525085.
A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection.
Sakurai M, Wakabayashi T, Kondo Y, Ikeda E, Watanabe K, Takei A, Okazaki H, Okada K, Ebihara K, Kakiuchi N, Ogawa S, Fukushima N, Ishibashi S.
Endocr J. 2023 Jun 28;70(6):573-579. doi: 10.1507/endocrj.EJ22-0578. Epub 2023 Mar 9.
